FindTrial
Sign In

V116

BIOLOGICAL11 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Pneumococcal DiseasePneumococcal InfectionPneumonia, Pneumococcal

Phase 1

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
CompletedNCT04168190
Merck Sharp & Dohme LLCPneumonia, Pneumococcal
Start: 2019-12-06End: 2021-07-12Updated: 2022-09-16
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
CompletedNCT04665050
Merck Sharp & Dohme LLCPneumococcal Infection
Start: 2021-02-04End: 2021-04-06Updated: 2023-10-04

Phase 3

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
CompletedNCT05393037
Merck Sharp & Dohme LLCPneumococcal Disease
Start: 2022-07-13End: 2024-01-25Updated: 2026-02-05
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
CompletedNCT05420961
Merck Sharp & Dohme LLCPneumonia, Pneumococcal
Start: 2022-07-12End: 2023-05-16Updated: 2024-10-26
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
CompletedNCT05425732
Merck Sharp & Dohme LLCPneumococcal Infection
Start: 2022-07-13End: 2023-05-18Updated: 2024-10-26
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
CompletedNCT05464420
Merck Sharp & Dohme LLCPneumococcal Disease
Start: 2022-08-12End: 2023-05-25Updated: 2024-09-24
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
CompletedNCT05526716
Merck Sharp & Dohme LLCPneumonia, Pneumococcal
Start: 2022-09-23End: 2023-06-21Updated: 2025-10-29
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
CompletedNCT05569954
Merck Sharp & Dohme LLCPneumococcal Disease
Start: 2022-11-07End: 2025-02-07Updated: 2026-03-02
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
CompletedNCT05633992
Merck Sharp & Dohme LLCPneumococcal Disease
Start: 2023-01-10End: 2023-05-24Updated: 2024-10-02
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
CompletedNCT05696080
Merck Sharp & Dohme LLCPneumococcal Infection
Start: 2023-02-13End: 2024-02-16Updated: 2026-03-03
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
CompletedNCT06177912
Merck Sharp & Dohme LLCPneumococcal Infection
Start: 2024-01-18End: 2025-02-26Updated: 2026-03-11

Related Papers

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.
2025-11-10
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.
2025-09-12
A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age.
2025-08-05
A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4).
2025-06-20
A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)
Vaccines2025-03-222 citations
P-45. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age with Increased Risk for Pneumococcal Disease
Open Forum Infectious Diseases2025-01-29
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)
Clinical Infectious Diseases2024-07-3125 citations
Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.
2024-07-0131 citations
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
2022-09-1560 citations